A significant shift in Canadian drug policy has occurred, as the regulators allow the availability of psilocybin hallucinogens for therapeutic applications. Previously, these substances were severely restricted, but a increasing body of research suggests they potentially offer benefits for psychological illnesses like anxiety. This change represent